Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients

An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients

This registry is intended to evaluate the impact of genomic test results towards selecting a first-line therapy option for newly diagnosed localized prostate cancer patients.

Inclusion Criteria:

• Newly diagnosed (≤6 months), untreated patients with histologically proven adenocarcinoma of the prostate that have the following characteristics.
• Clinically localized (no evidence on clinical or imaging studies of advanced disease).
• No hormonal therapy including LHRH (luteinizing hormone-releasing hormone) agonist or antagonist, anti-androgen, estrogens or exogenous androgens, when applicable.
• Sufficient amount of tissue remains from biopsy to perform genomic testing.

Exclusion Criteria:

• Patients with a known history of hypogonadism